Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

朝聚眼科
CHAOJU EYE CARE

Chaoju Eye Care Holdings Limited
朝聚眼科醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2219)

DISCLOSEABLE TRANSACTION
SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

Reference is made to the announcements of the Company dated September 27, 2024 and June 24, 2025 in relation to the subscription of structured deposit products offered by BOC in the total principal amount of RMB240 million (the "**September Deposit Products**") and RMB100 million (the "**June Deposit Products**"), respectively.

The Board announces that on August 22, 2025, Chaoju Medical Technology (an indirect wholly-owned subsidiary of the Company) has further subscribed for the Wealth Management Products in the total principal amount of RMB30 million offered by BOC.

The Subscriptions are funded by surplus cash of the Group and not by the proceeds from the Global Offering.

IMPLICATIONS UNDER THE LISTING RULES

As each of the September Deposit Products, the June Deposit Products and the Wealth Management Products are subscribed with the same bank (i.e. BOC), they would, in each case, be aggregated and treated as if the subscriptions were one transaction conducted with that bank for the purpose of computing the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As one or more of the applicable percentage ratios, in respect of the aggregated subscription amount of the September Deposit Products, the June Deposit Products and the Wealth Management Products at the relevant period, exceed 5% but are less than 25%, the Subscription of the Wealth Management Products, when aggregated with the September Deposit Products and the June Deposit Products constitute discloseable transactions of the Company and are hence subject to the reporting and announcement requirements but are exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

Reference is made to the announcements of the Company dated September 27, 2024 and June 24, 2025 in relation to the subscription of structured deposit products offered by BOC in the total principal amount of RMB240 million and RMB100 million, respectively. Save for the September Deposit Products and the June Deposit Products, there are no structured deposit products subscribed from BOC by the Company that remain outstanding immediately prior to the Subscription.

The Board announces that on August 22, 2025, Chaoju Medical Technology (an indirect wholly-owned subsidiary of the Company) has subscribed for the Wealth Management Products in the total principal amount of RMB30 million offered by BOC.

The Wealth Management Products

(I) Wealth Management Products (Z7001024000365)

Date of subscription:	August 22, 2025
Name of the wealth management products:	(Institutional Exclusive) BOC Wealth Management – Anxiang Tiantian (中銀理財 – 安享天添) (Z7001024000365)
Parties:	(a) Chaoju Medical Technology; and (b) BOC
Principal amount of subscription:	RMB30,000,000
Performance benchmark:	the performance benchmark of the Wealth Management Product is 1.80%-2.50% per annual. The performance benchmark is expressed as an annualized rate of return and is set by the product manager based on factors such as the product's nature, investment strategy and the experience. The performance benchmark is not the expected rate of return, does not represent the future performance or actual return of the product, and does not constitute any commitment or guarantee of return by the product manager.

Term of products:	No fixed term, the units may be redeemed at any business day. In the event of special circumstances requiring a temporary increase or decrease in the number of open days, the specific announcement of the product manager shall prevail.
Type of product and risk rating:	Non-principal-guaranteed with floating return and is regarded as a medium-to-low risk product by BOC

REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS

The Wealth Management Products are of medium-to-low risk nature with satisfactory liquidity, and the Subscriptions are carried out by the Company for treasury management purpose in order to enhance the utilization of and maximize the return on the surplus cash received from its business operations. The Subscriptions are funded by surplus cash of the Group and not by the proceeds from the Global Offering.

The Group expects that the Wealth Management Products will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. Further, the Group has implemented adequate and appropriate internal control procedures to ensure the Subscriptions would not affect the working capital or the operations of the Group, and that such investments would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the terms of the Wealth Management Products are fair and reasonable, and are on normal commercial terms and the Subscriptions are in the interests of the Company and the Shareholders as a whole.

INFORMATION ABOUT THE PARTIES

The Group

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. As of the date of this announcement, the Group operated a network of 31 ophthalmic hospitals and 29 optical centers spanning across 7 provinces, cities and autonomous regions in China. The ophthalmic hospitals are specialized in providing ophthalmic services and the optical centers provide a series of optical products and services to satisfy a wide array of requests from customers.

BOC

BOC is a joint stock company incorporated in the PRC with limited liability. BOC and its subsidiaries are principally engaged in the commercial banking business which provides services such as accepting deposits, making loans and offering basic investment products. BOC is listed on the Stock Exchange (Stock Code: 3988) and the Shanghai Stock Exchange (Stock Code: 601988).

As of the date of this announcement and to the best of the Director's knowledge, information and belief, having made all reasonable enquiries, BOC and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

IMPLICATION UNDER THE LISTING RULES

As each of the September Deposit Products, the June Deposit Products and the Wealth Management Products are subscribed with the same bank (i.e. BOC), they would, in each case, be aggregated and treated as if the subscriptions were one transaction conducted with that bank for the purpose of computing the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As one or more of the applicable percentage ratios, in respect of the aggregated subscription amount of the September Deposit Products, the June Deposit Products and the Wealth Management Products at the relevant period, exceed 5% but are less than 25%, the Subscription, when aggregated with the September Deposit Products and the June Deposit Products constitute discloseable transactions of the Company and are hence subject to the reporting and announcement requirements but are exempted from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following words and expressions shall have the meaning ascribed to them below:

"Board"	the board of Directors
"BOC"	Bank of China Limited
"Chaoju Medical Technology"	Chaoju Medical Technology Co., Ltd.* (朝聚醫療科技有限公司), a limited liability company established under the laws of the PRC on November 16, 2015, an indirect wholly-owned subsidiary of our Company, formerly known as Chaoju Medical Technology Equity Co., Ltd.* (朝聚醫療科技股份有限公司)

"China" or the "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to "China" and the "PRC" do not apply to Hong Kong, Macau and Taiwan
"Company"	Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020
"Director(s)"	director(s) of the Company
"Global Offering"	the Hong Kong Public Offering and the International Offering (both as defined in the Prospectus)
"Group"	the Company together with its subsidiaries
"HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Prospectus"	the prospectus of the Company published on June 24, 2021
"RMB"	the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the share capital of the Company with nominal value of HK$0.00025 each
"Shareholder(s)"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subscription(s)"	subscription(s) of the Wealth Management Products

"Wealth Management Products"	the Wealth Management Products offered by BOC and subscribed by the Group on August 22, 2025, the details of which are set out in this announcement
"%"	per cent

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, August 22, 2025

As of the date of this announcement, the board of directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

* *The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.*